9.800USD+4.93%Mkt Cap: 88.30M USDP/E: —Last update: 2026-05-22
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleuce…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap88.30M USD
Enterprise Value84.87M USD
Revenue (TTM)23.14M USD
Gross Profit99.56M USD
Net Income (TTM)32.69M USD
Revenue/Share1.730 USD
Last Price9.800 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0465131078
Valuation
P/E (Trailing)—
P/E (Forward)5.71
PEG—
EV/EBITDA11.09
EV/Revenue3.67
P/S3.64
P/B-2.13
EPS (TTM)-1.22
EPS (Forward)1.64
52W Range
3.92039% of range19.14
52W High19.14 USD
52W Low3.920 USD
Profitability
Gross Margin82.44%
Oper. Margin-652.91%
EBITDA Margin33.06%
Profit Margin27.07%
ROE-84.90%
ROA161.54%
Growth
Revenue Growth-99.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.94M USD
CapEx (TTM)—
FCF Margin-27.62%
FCF Yield-7.24%
Net Debt716.00K USD
Net Debt/EBITDA0.09
Balance Sheet
Debt/Equity-0.27
Current Ratio2.16
Quick Ratio1.48
Book Value/Sh-4.3830 USD
Cash/Share0.9280 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJun 20, 2024
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)13.67 USD
Target Range10.00 USD – 18.00 USD
# Analysts3
Ownership
Shares Out.9.01M
Float4.74M
Insiders16.66%
Institutions48.77%
Short Interest
Short Ratio4.7d
Short % Float5.25%
Short % Out.3.60%
Shares Short306.09K
Short (prev mo.)327.07K
Technical
SMA 506.008 (+63.1%)
SMA 20010.16 (-3.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.85M
Avg Vol (10d)710.80K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—